Doxorubicin Dose Adjustment for Abnormal Liver Function Tests

Dose Adjustment Guidelines

The American College of Cardiology recommends reducing doxorubicin doses by 50% for patients with bilirubin levels between 1.2-3.0 mg/dL to prevent increased toxicity while maintaining efficacy 1
For patients with bilirubin levels greater than 3.0 mg/dL, a 75% dose reduction or consideration of alternative therapy is recommended to minimize toxicity 1
For patients with ALT/AST levels less than 3× ULN, no dose adjustment is required, but increased monitoring is recommended 1
For patients with ALT/AST levels between 3-5× ULN, a 25% dose reduction should be considered 1
For patients with ALT/AST levels greater than 5× ULN, a 50% dose reduction or temporary hold until improvement is recommended 1
For patients with ALT/AST levels greater than 8-10× ULN, chemotherapy should be held until improvement to less than 5× ULN 1

Baseline liver function tests, including bilirubin, ALT, AST, alkaline phosphatase, and albumin, should be assessed before initiating doxorubicin therapy 1
Liver function should be monitored before each cycle of doxorubicin 1
Monitoring frequency should be increased when liver test elevations are detected 1

Cumulative doses of doxorubicin greater than 300 mg/m² are associated with an increased risk of cardiotoxicity, which may be exacerbated in patients with liver dysfunction 2

Rechallenge with doxorubicin should be based on a benefit-risk assessment and characteristics of the original liver injury 1
If liver function returns to baseline or near baseline, consider reintroducing doxorubicin at a reduced dose of 25-50% 1
Rechallenge is not recommended when there is no evidence of benefit for the patient, alternative treatment options with less hepatotoxicity are available, or the patient experienced severe hepatocellular injury 1